$89.600
+1.425 (+1.59%)收盘时
IFF 资讯
IFF 事件
IFF Releases 'Dear Dairy: The Life Stages Guide'
IFF published its latest resource, Dear Dairy: The Life Stages Guide. This strategic guide reveals how manufacturers can unlock new opportunities by aligning dairy innovation with consumers' evolving needs. "Dairy is one of the few categories that evolves alongside consumers throughout their lives," said Rogerio de Almeida Prado, vice president of Global Dairy & BBC for IFF Taste. "Over time, expectations change. What builds trust in childhood may need to support identity, convenience or vitality later in life. The next wave of dairy innovation will be defined not by a single trend, ingredient or claim, but by an understanding of what consumers need at different times of their lives - and why."
IFF Launches New Omni-Bos PHY Phytase Enzyme
IFF announced the launch of Omni-Bos PHY, a novel phytase enzyme designed specifically for dairy cattle. The technology helps producers improve nutrient utilization and feed efficiency by unlocking nutrients already present in feed, enabling cows to derive greater value from existing feed ingredients. Omni-Bos PHY will initially launch in the Middle East, Africa and Asia-Pacific regions.
Charles River Stock Rises to $260.96
Notable gainers among liquid option names this morning include Charles River (CRL) $260.96 +26.84, Wynn Resorts (WYNN) $108.44 +10.84, International Flavors (IFF) $86.29 +5.40, Newmont Mining (NEM) $103.93 +6.20, and Booking Holdings (BKNG) $206.00 +11.73.
IFF Reports Q2 Revenue of $1.954B
Reports Q2 revenue $1.954B, consensus $2.69B. "IFF delivered a strong first half of 2026 on a continuing operations basis," said Erik Fyrwald, CEO of IFF. "Performance was driven by volume growth, disciplined margin execution and robust free cash flow generation. These results reflect the strength of our commercial and innovation pipelines and the actions underway to improve efficiency and cash flow across the company."
IFF Enters Agreement to Sell Botanical Extracts to SuanNutra
IFF announced that it has entered into an agreement with SuanNutra, a Carbyne Equity Partners portfolio company and global provider of science-backed branded and functional ingredients, to sell its portfolio of botanical extracts, vitamins and minerals, and food enhancement activities, including its range of natural colors and antioxidants and certain localized flavor activities in Peru. The portfolio serves a broad range of food, beverage and nutritional end markets through a comprehensive selection of customized solutions. The transaction includes operations that generated revenues of approximately $170M in 2025. Collectively, the activities included in the transaction employ about 600 people and operate across five manufacturing facilities in Europe, the U.S. and Latin America. Financial terms of the deal were not disclosed. The companies expect to close the sale by the end of 2026, subject to customary closing conditions, including regulatory clearances and the satisfaction of applicable consultation requirements. Alantra acted as financial advisor to IFF and DLA Piper acted as legal counsel.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。